The present invention relates to a method of treating chronic fatigue syndrome not associated with an HIV infection. In the method of the present invention patients are administered a pharmaceutically acceptable carrier together with(1) a neuropsychiatrically effective amount of a linear peptide of formula (I):whereinR.sup.a is Ala, D-Ala or Cys-Ala-, andR.sup.6 is Thr, Thr-amide, Thr-Cys or Thr-Cys-amide,or a derivative of the peptide or a physiologically acceptable salt thereof; or(2) a neuropsychiatrically effective amount of a linear peptide of formula (II):whereinR.sup.1 is X-Y or Y when Y is Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu-, and X is Cys;R.sup.2 is Thr-, Ser- or Asp;R.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp;R.sup.4 is Tyr; andR.sup.5 is Z-X or Z wherein Z is any amino acid and X is Cys,or a derivative of the peptide or a physiologically acceptable salt thereof; or(e) a neuropsychiatrically effective amount of a linear peptide of formula (III):whereinR.sup.x is Ala-R.sup.1, D-Ala-R.sup.1 or X-Ala-R.sup.1 wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup.4 are as defined above, and R.sup.y is Thr-, Thr-amide or Thr-Cys, or a derivative of the peptide or a physiologically acceptable salt thereof.

The United States of America as represented by the Secretary of Health

Composition for the treatment of chronic fatigue syndrome

Composition including: (A) 50% to 95% of at least one semicrystalline polyamide of formula A/Z in which: A is an aliphatic repeating unit chosen from a unit obtained from the polycondensation of at least one amino acid and a unit obtained from the polycondensation of at least one lactam or a unit X.Y obtained from the polycondensation of at least one diamine, and of at least one dicarboxylic acid, and Z represents another polyamide and is included from 0 to 20%; (B) 5% to 50% of at least one semicrystalline copolyamide comprising amide units (Ba1) and including polyether units (Ba2), having a glass transition temperature (T.sub.g) below 75.degree. C.; (C) 0% to 20% by weight of fibres and/or fillers, (D) 0% to 20% of at least one impact modifier, (E) 0% to 5% of at least one additive, for the manufacture of a sports article.

ARKEMA FRANCE

Compositions of polyamide and PEBA for the injection of fatigue-resistant rigid parts

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

Pfizer Inc.

Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors

Provided is a thermoplastic resin composition in which a modified rubber excellent in low temperature resistance is dispersedly added in a polyamide resin matrix to improve the low temperature resistance (cyclic fatigue resistance) of the polyamide resin, the composition maintaining its fluidity even at a high content of modified rubber, thus allowing film formation, and exhibiting excellent low temperature resistance. The thermoplastic resin composition includes a polyamide resin (A) and a modified rubber (B) having an acid anhydride group or an epoxy group and is characterized in that the modified rubber (B) having an acid anhydride group or an epoxy group is modified with a hydrogen bonding compound (C) having a functional group reacting with an acid anhydride group or an epoxy group and a functional group capable of hydrogen bonding with an amide bond or a hydroxyl group. In addition, the polyamide resin (A) is preferably modified with a compound capable of bonding to a terminal amino group of the polyamide resin. The thermoplastic resin composition is suitably used for production of tires, hoses and the like.

amide/fatigue

Composition for the treatment of chronic fatigue syndrome

Compositions of polyamide and PEBA for the injection of fatigue-resistant rigid parts

Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors

Thermoplastic resin composition

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht